• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Samaritan Pharmaceuticals, Inc. (Samaritan) is an entrepreneurial biopharmaceutical company, focused on commercializing therapeutic products to relieve the suffering of patients with Alzheimer's disease, cancer, cardiovascular disease, human immunodeficiency virus (HIV), and Hepatitis C. Samaritan also focuses on commercializing its acquired marketing and sales rights to sell 15 marketed revenue-generating products, in Greece, and/or various Eastern European countries. The Company has partnered its oral entry inhibitor HIV drug SP-01A, a drug that has demonstrated safety and efficacy, in Phase II clinical trials, with Pharmaplaz, Ireland to advance to Phase III clinical trials. In addition, it aims to commercialize three market drug candidates with late-stage preclinical development programs. On March 1, 2007, Samaritan completed its acquisition of Metastatin Pharmaceuticals.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
GREESON JANET CHIEF EXECUTIVE OFFICER |
|
1,833,356 | 2008-09-11 | 0 |
|
BOYLE EUGENE CHIEF FINANCIAL OFFICER |
|
1,109,207 | 2008-09-11 | 0 |
|
LANG THOMAS ARNOLD CHIEF DRUG DEVELOPMENT OFFICER |
|
162,239 | 2008-07-28 | 0 |
|
112,465 | 2008-07-28 | 0 | |
|
AYALA JACINTO L |
|
67,500 | 2008-01-30 | 0 |
|
52,500 | 2008-01-30 | 0 | |
|
THOMPSON CYNTHIA C |
|
315,596 | 2007-12-31 | 0 |
|
WINN H THOMAS |
|
167,501 | 2007-12-31 | 0 |
|
565,565 | 2007-12-31 | 0 | |
|
SALDI JUGAN DR |
|
48,564 | 2007-12-31 | 0 |
|
LECANU LAURENT |
|
8,334 | 2007-12-31 | 0 |
|
GARCIA JULIO L. |
|
37,500 | 2007-12-31 | 0 |
|
PAPADOPOULOS VASSILI DR |
|
250,000 | 2007-06-12 | 0 |
|
BESSERT DOUGLAS |
|
30,000 | 2006-08-08 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
